AsianScientist (Mar. 2, 2015) – Eisai China Inc. (ECI), a subsidiary of Japanese pharmaceutical company Eisai, has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant located within the Suzhou Industrial Park. The new facility will expand its existing OSD production facility within the same industrial park.
ECI has been producing OSD products such as Methycobal, Aricept and Pariet for the Chinese market at the old plant. However, in expectation of increased demand for Eisai products in the growing Chinese pharmaceutical market, it has become necessary to establish a new plant that will enable future capacity expansion aimed at strengthening the stable supply chain and improving production efficiency.
The new lot of land, which is more than five times larger than the old plant, was secured in 2010. In November 2014, a parenteral facility for the local production of injection products was established at this site as the new plant. In addition to the OSD production facility, ECI will also build an administration building at the site.
Expected to stand three floors above ground and containing floor space of approximately 20,900 m2, the new OSD facility will handle the manufacturing and packaging of oral solid dose products for the domestic Chinese market. Construction is scheduled to begin in first half of fiscal 2016 and finish during the second half of fiscal 2017, with operations to commence in the second half of fiscal 2018. Once operations have commenced at the new OSD facility, the old plant will be closed down.
—–
Source: Eisai.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
